Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up
https://www.zacks.com/stock/news/2197568/blueprint-bpmc-gets-ec-nod-for-ayvakit-expanded-use-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197568
Dec 13, 2023 - Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.
0
Pages: 12
<Page 2